fy model updat
updat sale estim
repres cc growth adj pmr divestitur ep estimate
exhibit vs guidanc estim
sale prior repres cc growth
estim full year divestitur adj guidanc msd adj cc growth
model ep prior recalcul base
within guidanc exhibit given ep tailwind fx
repres cc ep growth report
valuat risk continu see upsid share price given
view like enjoy msd sale growth compound-annual-growth-rate
modest margin expansion/shar buyback drive hsd ep growth
compound-annual-growth-rate pt base rel valuat framework
regress forward top-lin compound-annual-growth-rate rel forward price-to-earnings med-
tech stock suggest rel forward multipl rel
 analysi suggest forward multipl in-lin year
 averag month price target actual repres
forward multipl estim fy ep begin
end april reflect discount market mdt mid-singl
digit top-lin proven durabl currency/oth frequent prevent
attain aspir doubl digit cash ep growth investor
like welcom improv perform latter regard better
understanding/commit specif oper margin improv goal
would help ration doubl digit ep growth mid-singl digit top-lin
growth rate risk pt includ end-market opac top line volatil
greater expect key end market weak failur meet margin
continu pg
tr target
exhibit revenu varianc vs consensu segment product categori
page
exhibit revenu varianc vs consensu segment product categori cont
page
page
incom statementstrh estimatesactualconsensusno ofmdt actual vs consensu cc incom incl expens ni ex attribut estimatesactualconsensusno ofmdt actual vs consensusmargin margin incl medtron plc
exhibit fy revenu varianc vs consensu segment product categori
page
exhibit fy revenu varianc vs consensu segment product categori cont
page
page
note restat pmr divestitur compani file factset strh estim
page
period million ens ens net incom ex ni ex attribut analysisgross margin excl margin incl margin excl margin attribut analysi y/i cc pf pmr incom attribut medtron plc
world largest medic devic compani leadership across major market
compani four busi segment cardiac vascular minim invas technolog
restor therapi diabet headquart dublin ireland
continu see upsid share price given view like enjoy msd sale
growth compound-annual-growth-rate modest margin expansion/shar buyback drive hsd ep
growth compound-annual-growth-rate mdt mid-singl digit top-lin proven durabl currency/
frequent prevent attain aspir doubl digit cash ep growth
investor like welcom improv perform latter regard better understanding/
commit specif oper margin improv goal would help ration doubl digit
ep growth mid-singl digit top-lin growth rate
valuat risk
pt base rel valuat framework regress forward top-lin compound-annual-growth-rate
rel forward price-to-earnings med-tech stock suggest rel forward multipl rel
 analysi suggest forward multipl in-lin year averag
month price target actual repres forward multipl estim fy ep
begin end april reflect discount market risk pt includ
end-market opac top line volatil greater expect key end market weak failur
meet margin expans expect
compani mention note
bruce nudel herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
